| Literature DB >> 28506771 |
Marcelo Sperandio1, Ana Paula D Demasi1, Elizabeth F Martinez1, Sara O Saad2, Fernando V Pericole2, Karla P Vieira2, Nadir S Freitas1, Vera C Araújo1, Amy Louise Brown1, Juliana Trindade Clemente-Napimoga1, Marcelo Henrique Napimoga3.
Abstract
Multiple myeloma (MM) is characterised by intense protein folding and, consequently endoplasmic reticulum (ER) stress. The prostaglandin 15d-PGJ2 is able to raise oxidative stress levels within the cell and potentially trigger cell death. The aim of this study was to evaluate the antineoplastic effect of 15d-PGJ2 on MM in vitro and in vivo via ER and oxidative stress pathways. MM.1R and MM.1S cell lines were treated with 15d-PGJ2 at 1-10μM and evaluated with regard to proliferation, mRNA expression of PRDX1, PRDX4, GRP78, GRP94, CHOP, BCL-2 and BAX. Stress data was validated via oxidized glutathione assays. MM.1R cells were inoculated into NOD/SCID mice, which were subsequently treated daily with 15d-PGJ2 at 4mg/kg or vehicle (control), with tumour volume being monitored for 14days. 15d-PGJ2 reduced cell proliferation, induced cell death and apoptosis at 5μM and 10μM and Stress-related genes were upregulated at the same doses. Oxidized glutathione levels were also increased. 15d-PGJ2 at 4mg/kg in vivo halted tumour growth. In conclusion, 15d-PGJ2 induced myeloma cell death via ER stress in vitro. 15d-PGJ2 in vivo also inhibited tumour growth.Entities:
Keywords: Antineoplastic agents; Apoptosis; Endoplasmic reticulum stress; Multiple myeloma; Peroxiredoxins; Prostaglandins; Unfolded protein response
Mesh:
Substances:
Year: 2017 PMID: 28506771 DOI: 10.1016/j.yexmp.2017.05.003
Source DB: PubMed Journal: Exp Mol Pathol ISSN: 0014-4800 Impact factor: 3.362